Urologie Bayenthal in Köln
Welcome,         Profile    Billing    Logout  
 2 Trials 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Klier, Jörg
NCT02106572 / 2013-003446-16: Therapeutic Instillation of Mistletoe

Recruiting
3
548
Europe, RoW
abnobaVISCUM 900, viscum album extract, mistletoe extract, abnobaVISCUM, Mitomycin C, MMC, Mitomycin
Abnoba Gmbh
Superficial Bladder Cancer
06/28
12/28
ARASAFE, NCT05676203: A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients

Active, not recruiting
3
250
Europe
Standard ADT (androgen deprivation therapy), Standard Darolutamide, Docetaxel
Jena University Hospital, Bayer
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
07/25
01/27
PROCARE, NCT06835218: - PROstate Cancer Real World Evidence Registry

Recruiting
N/A
5000
Europe
UroTrials Company (GmbH), Novartis Pharmaceuticals, AstraZeneca
Prostate Cancer, Biochemical Recurrence of Malignant Neoplasm of Prostate, Non-metastatic Castration-resistant Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Metastatic Castration-resistant Prostate Cancer
03/31
12/32
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Klier, Jörg
NCT02106572 / 2013-003446-16: Therapeutic Instillation of Mistletoe

Recruiting
3
548
Europe, RoW
abnobaVISCUM 900, viscum album extract, mistletoe extract, abnobaVISCUM, Mitomycin C, MMC, Mitomycin
Abnoba Gmbh
Superficial Bladder Cancer
06/28
12/28
ARASAFE, NCT05676203: A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients

Active, not recruiting
3
250
Europe
Standard ADT (androgen deprivation therapy), Standard Darolutamide, Docetaxel
Jena University Hospital, Bayer
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
07/25
01/27
PROCARE, NCT06835218: - PROstate Cancer Real World Evidence Registry

Recruiting
N/A
5000
Europe
UroTrials Company (GmbH), Novartis Pharmaceuticals, AstraZeneca
Prostate Cancer, Biochemical Recurrence of Malignant Neoplasm of Prostate, Non-metastatic Castration-resistant Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Metastatic Castration-resistant Prostate Cancer
03/31
12/32

Download Options